Cardiac Arrest (CA)BPT-PCASNCT07769086
Breakthrough Platform Trial for PCAS
A study testing Head Positioning in people with Cardiac Arrest (CA) and Post Cardiac Arrest Syndrome, run by Kagawa University at 12 sites in Japan.
Trial summary
The goal of this platform clinical trial is to evaluate whether specific post-cardiac arrest care strategies can improve neurological recovery and survival in adult patients who remain comatose after return of spontaneous circulation (ROSC) following cardiac arrest and require intensive care management. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cardiac Arrest (CA), Post Cardiac Arrest Syndrome
- What is being tested?
- Head Positioning
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 630 participants
- Where
- 12 sitesJapan
- Study dates
- 1 Sep 2026to 30 Jun 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Master Platform Eligibility:
- Adult patients aged 18 years or older
- Return of spontaneous circulation after cardiac arrest
- Persistent coma after return of spontaneous circulation (GCS motor score <6)
- Requirement for intensive care management
- Head Positioning Domain Eligibility:
Show all 12Show fewer
- Non-traumatic out-of-hospital or in-hospital cardiac arrest
- Systolic blood pressure ≥80 mmHg or mean arterial pressure ≥65 mmHg (fluid resuscitation and vasopressor use permitted; transient hypotension recoverable within 20-30 minutes is acceptable)
- Temperature Control Domain Eligibility:
- Initial non-shockable cardiac arrest rhythm
- Systolic blood pressure ≥80 mmHg or mean arterial pressure ≥65 mmHg (fluid resuscitation and vasopressor use permitted; transient hypotension recoverable within 20-30 minutes is acceptable)
- Ability to initiate temperature control therapy within 240 minutes after return of spontaneous circulation
Who cannot join
- Master Platform Exclusion:
- Refusal of intensive care management
- Extracorporeal cardiopulmonary resuscitation (ECPR)
- Pregnancy or possible pregnancy
- Cardiac arrest due to intracranial hemorrhage, subarachnoid hemorrhage, cerebral infarction, acute aortic dissection, or terminal cancer (including suspected cases)
- Severe chronic obstructive pulmonary disease requiring home oxygen therapy
Show all 25Show fewer
- Poor pre-arrest neurological function (CPC 3-4) or poor overall functional status (OPC 3-4)
- Pre-existing do-not-attempt-resuscitation (DNAR) order
- Expected early death
- Inability to obtain consent from a legally acceptable representative or the participant
- Enrollment judged inappropriate by the investigator
- Head Positioning Domain Exclusion:
- Body temperature <30°C on hospital arrival
- Refusal of consent for participation in the head positioning domain
- Enrollment judged inappropriate by the investigator
- Patients using Impella® (a percutaneous mechanical circulatory support catheter) at the time of ICU admission
- Patients using an intra-aortic balloon pump (IABP) at the time of ICU admission
- Patients for whom feedback-controlled device-based temperature management or fever prevention is not being performed and is not planned at the time of ICU admission
- Temperature Control Domain Exclusion:
- rCAST <4.5
- rCAST ≥17.0
- Traumatic cardiac arrest
- Body temperature <30°C on hospital arrival
- Refusal of consent for participation in the temperature control domain
- Enrollment judged inappropriate by the investigator
Trial locations and contacts
12 sites in 1 country. Contact the study team or a site near you to ask about taking part.
12 sites in 1 country
Japan12 sites
TMG Asaka Medical Center
Asaka, Saitama, 3510023
Yusuke Morohashi, +81-48-466-2055, yskmoro.yuyu0507@gmail.com
Nippon medical school hospital
Bunkyō-Ku, Tokyo, 113-8603
Toru Takiguchi, +81-3-3822-2131, toru-takiguchi@nms.ac.jp
Chiba Kaihin Municipal Hospital
Chiba, Chiba, 2610012
Yosuke Homma, +81-43-277-7711, jazz.dr.homma@gmail.com
Hiroshima University Hospital
Hiroshima, Hiroshima, 7348551
Mitsuaki Nishikimi, +81-82-257-5456, nishikim@hiroshima-u.ac.jp
Aso Iizuka Hospital
Iizuka, Fukuoka, 8208505
Daisuke Kawakami, +81-948-22-3800, dsk_kwkm_n9s@hotmail.co.jp
Kagawa University Hospital
Kita-gun, Kagawa-ken, 761-0701
Kenya Kawakita, +81-87-891-2382, kawakita.kenya@kagawa-u.ac.jp
Hyogo Emergency Medical Center
Kobe, Hyōgo, 651-0073
Takeshi Nishimura, +87-78-241-3131, t-nishimura@hemc.jp
Kyoto Katsura Hospital
Kyoto, Kyoto, 6158256
Taiga Sunada, +81-75-391-5811, sunada.taiga@gmail.com
Musashino Red Cross Hospital
Musashino, Tokyo, 1800023
Hidetaka Suzuki, +81-422-32-3111, h.suzuki@musashino.jrc.or.jp
Okayama University Hospital
Okayama, Okayama-ken, 7008558
Tetsuya Yumoto, +81-86-235-7427, tyumoto@cc.okayama-u.ac.jp
National Hospital Organization Sendai Medical Center
Sendai, Miyagi, 9838520
Yu Kawazoe, +81-22-293-1111, yu.kawazoe.b7@tohoku.ac.jp
Tokyo Metropolitan Bokutoh Hospital
Sumida-ku, Tokyo, 1308575
Kazuhiro Sugiyama, +81-3-3633-6151, kazusugi0422@hotmail.com
About this study
Official title: Breakthrough Platform Trial for Post Cardiac Arrest Syndrome
The goal of this platform clinical trial is to evaluate whether specific post-cardiac arrest care strategies can improve neurological recovery and survival in adult patients who remain comatose after return of spontaneous circulation (ROSC) following cardiac arrest and require intensive care management.
This multicenter cluster-randomized crossover platform trial (BPT-PCAS) evaluates post-cardiac arrest care strategies within a shared master protocol structure. Participating hospitals are randomized at the institutional level to predefined treatment strategies for fixed study periods and subsequently cross over to alternative strategies according to a predefined allocation schedule.
Read more
The platform is designed to accommodate multiple independent intervention domains, each evaluating a different post-cardiac arrest care strategy under shared eligibility criteria, infrastructure, data management systems, and follow-up procedures. Participants may be enrolled in one or more active intervention domains according to platform availability and eligibility.
Participants will receive the post-cardiac arrest care strategy assigned to their participating hospital during the study period while otherwise undergoing standard intensive care management according to local practice and study protocols.
Participants will be followed for neurological outcomes including modified Rankin Scale (mRS), mortality, and safety outcomes at hospital discharge, 30 days, and 90 days after hospital admission.
Read the detailed description
BPT-PCAS (Breakthrough Platform Trial for Post-Cardiac Arrest Syndrome) is a multicenter platform trial designed to evaluate whether early post-cardiac arrest care strategies can improve neurological recovery and survival in adult patients who remain comatose after return of spontaneous circulation (ROSC) following cardiac arrest and require intensive care management.
Despite advances in resuscitation and intensive care medicine, prognosis after post-cardiac arrest syndrome (PCAS) remains poor, particularly because of hypoxic-ischemic brain injury and systemic circulatory dysfunction. Many aspects of post-resuscitation intensive care management, including positioning strategies and targeted temperature management, are widely used in clinical practice but remain supported by limited high-quality randomized evidence, particularly during the ultra-early post-ROSC period.
BPT-PCAS is designed as a pragmatic multicenter cluster-randomized crossover platform trial conducted in Japan. Participating hospitals are randomized at the institutional level to predefined treatment strategies for fixed study periods. Hospitals subsequently cross over to alternative treatment strategies every 6 months according to a predefined allocation schedule. Randomization occurs at the hospital level rather than the individual patient level in order to facilitate immediate implementation of time-sensitive post-cardiac arrest interventions during emergency care.
The platform uses a master protocol structure with shared eligibility criteria, infrastructure, data management systems, and follow-up procedures across multiple intervention domains. Adult patients with persistent coma after ROSC who require intensive care are screened for eligibility under the master protocol. Individual domains may apply additional domain-specific inclusion and exclusion criteria.
The current platform includes multiple intervention domains evaluating different post-cardiac arrest care strategies.
One domain evaluates early head positioning strategies during intensive care management. This domain compares head elevation positioning (30°-45°) with near-supine positioning (0°-10°) initiated early after ICU admission in order to determine whether head positioning influences neurological recovery, mortality, and complications associated with cerebral perfusion, intracranial pressure, or respiratory management.
Another domain evaluates early targeted temperature management strategies in patients with non-shockable cardiac arrest rhythms. This domain compares early hypothermia (33-34°C) with normothermia (36-37.5°C) initiated as early as possible after ROSC in order to evaluate whether early temperature control improves neurological outcomes and survival.
Participants may simultaneously participate in more than one intervention domain when eligibility criteria are met. Aside from the assigned study interventions, all other intensive care management is performed according to local institutional practice and study protocols.
The primary and secondary outcomes differ according to each intervention domain and include neurological outcomes assessed using the modified Rankin Scale (mRS), mortality, and predefined safety outcomes. Follow-up assessments are performed during hospitalization and at 30 and 90 days after hospital admission.
Because eligible patients are critically ill and frequently incapable of providing prospective informed consent at the time of enrollment, this study permits deferred consent procedures in accordance with Japanese ethical guidelines for emergency research. Consent from legally acceptable representatives or patients themselves is obtained as soon as feasible after hospital admission whenever possible.
The study also includes predefined interim analyses and centralized data management using REDCap-based electronic data capture systems. Statistical analyses are performed using intention-to-treat principles with methods appropriate for cluster-randomized crossover trial designs.
- Conditions
- Cardiac Arrest (CA), Post Cardiac Arrest Syndrome
- Being tested
- Head Positioning, Temperature Control
- Keywords
- platform trial, cluster randomized trial, head positioning, Temperature control
- Medical subject headings
- Heart Arrest, Post-Cardiac Arrest Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Head PositioningProcedure or surgery
Institution-level assignment to predefined head positioning strategies during post-cardiac arrest intensive care management, including head elevation (30°-45°) or near-supine positioning (0°-10°).
Temperature ControlOther
Institution-level assignment to predefined temperature control strategies during post-cardiac arrest intensive care management, including targeted hypothermia (33-34°C) or normothermia/fever prevention strategies (36-37.5°C).
| Study group | Role | What they receive |
|---|---|---|
| Head Positioning Strategy (near-supine vs head elevation) | Experimental | Participants receive institutionally assigned post-cardiac arrest head positioning strategies according to the cluster-randomized crossover platform protocol, including head elevation (30°-45°) or near-supine positioning (0°-10°). Receives: Procedure: Head Positioning |
| Temperature Control Strategy (hypothermia vs normothermia) | Experimental | Participants receive institutionally assigned post-cardiac arrest temperature control strategies according to the cluster-randomized crossover platform protocol, including targeted hypothermia (33-34°C) or normothermia/fever prevention strategies (36-37.5°C). Receives: Other: Temperature Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Favorable neurological outcome (modified Rankin Scale ≤3) on Day 90 in the head positioning domain
Comparison of Favorable neurological outcome (modified Rankin Scale ≤3) on Day 90 between institutionally assigned head positioning strategies in adult patients with post-cardiac arrest syndrome.
Measured: 90 days after hospital admission
Favorable neurological outcome (modified Rankin Scale ≤3) on Day 90 in the temperature control domain
Comparison of neurological outcomes between institutionally assigned temperature control strategies in adult patients with post-cardiac arrest syndrome and non-shockable initial rhythms.
Measured: 90 days after hospital admission
Secondary outcomes (4)
mRS ≤3 on Day 30
Comparison of neurological outcome (mRS ≤3) on Day 30 between institutionally assigned head positioning strategies in adult patients with post-cardiac arrest syndrome.
Measured: 30 days after hospital admission
mRS ≤3 on Day 30
Comparison of neurological outcome (mRS ≤3) on Day 30 between institutionally assigned temperature control strategies in adult patients with post-cardiac arrest syndrome and non-shockable initial rhythms.
Measured: 30 days after hospital admission
All-cause mortality on Day 30 and Day 90
Comparison of all-cause mortality on Day 30 and Day 90 between institutionally assigned head positioning strategies in adult patients with post-cardiac arrest syndrome.
Measured: 30 days and 90 days after hospital admission
All-cause mortality on Day 30 and Day 90
Comparison of all-cause mortality on Day 30 and Day 90 between institutionally assigned temperature control strategies in adult patients with post-cardiac arrest syndrome and non-shockable initial rhythms.
Measured: 30 days and 90 days after hospital admission
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2026
- Study start1 Sep 2026 (estimated)
- Primary completion31 Mar 2031 (estimated)
- Study completion30 Jun 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac Arrest (CA)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- This study is a multicenter cluster-randomized crossover platform trial evaluating post-cardiac arrest care strategies in adult patients with post-cardiac arrest syndrome. Participating hospitals are assigned to predefined intervention strategies at the institutional level and cross over between strategies at predefined intervals. The platform includes multiple intervention domains, including head positioning and temperature control strategies. Individual participants may be enrolled in one or more active intervention domains according to platform availability and eligibility. Enrollment reflects Domain 1 (head positioning, n=630); some patients are co-enrolled in Domain 2 (temperature control, n=240) based on rhythm eligibility
- Masking
- None (open label)
- Enrolment
- 630 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kagawa University
- Sponsor type
- University, hospital or other
- Collaborators
- Becton, Dickinson and Company
- Responsible party
- Principal investigator, Yasuhiro Kuroda, Kagawa University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07769086
- Sponsor's protocol ID
- bpt-pcas
- Acronym
- BPT-PCAS
- Status last verified
- Aug 2026
- First submitted
- 12 Aug 2026
- Last updated
- 17 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Breakthrough Platform Trial for Post Cardiac Arrest Syndrome
- ClinicalTrials.gov ID
- NCT07769086
- Acronym / sponsor ID
- BPT-PCAS / bpt-pcas
- Conditions
- Cardiac Arrest (CA), Post Cardiac Arrest Syndrome
- Keywords
- platform trial, cluster randomized trial, head positioning, Temperature control
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 630 participants (estimated)
- Lead sponsor
- Kagawa UniversityUniversity, hospital or other
- Collaborators
- Becton, Dickinson and Company
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 31 Mar 2031 (estimated)
- Study completion
- 30 Jun 2031 (estimated)
- First posted
- 17 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this platform clinical trial is to evaluate whether specific post-cardiac arrest care strategies can improve neurological recovery and survival in adult patients who remain comatose after return of spontaneous circulation (ROSC) following cardiac arrest and require intensive care management.
This multicenter cluster-randomized crossover platform trial (BPT-PCAS) evaluates post-cardiac arrest care strategies within a shared master protocol structure. Participating hospitals are randomized at the institutional level to predefined treatment strategies for fixed study periods and subsequently cross over to alternative strategies according to a predefined allocation schedule.
The platform is designed to accommodate multiple independent intervention domains, each evaluating a different post-cardiac arrest care strategy under shared eligibility criteria, infrastructure, data management systems, and follow-up procedures. Participants may be enrolled in one or more active intervention domains according to platform availability and eligibility.
Participants will receive the post-cardiac arrest care strategy assigned to their participating hospital during the study period while otherwise undergoing standard intensive care management according to local practice and study protocols.
Participants will be followed for neurological outcomes including modified Rankin Scale (mRS), mortality, and safety outcomes at hospital discharge, 30 days, and 90 days after hospital admission.
Detailed description
BPT-PCAS (Breakthrough Platform Trial for Post-Cardiac Arrest Syndrome) is a multicenter platform trial designed to evaluate whether early post-cardiac arrest care strategies can improve neurological recovery and survival in adult patients who remain comatose after return of spontaneous circulation (ROSC) following cardiac arrest and require intensive care management.
Despite advances in resuscitation and intensive care medicine, prognosis after post-cardiac arrest syndrome (PCAS) remains poor, particularly because of hypoxic-ischemic brain injury and systemic circulatory dysfunction. Many aspects of post-resuscitation intensive care management, including positioning strategies and targeted temperature management, are widely used in clinical practice but remain supported by limited high-quality randomized evidence, particularly during the ultra-early post-ROSC period.
BPT-PCAS is designed as a pragmatic multicenter cluster-randomized crossover platform trial conducted in Japan. Participating hospitals are randomized at the institutional level to predefined treatment strategies for fixed study periods. Hospitals subsequently cross over to alternative treatment strategies every 6 months according to a predefined allocation schedule. Randomization occurs at the hospital level rather than the individual patient level in order to facilitate immediate implementation of time-sensitive post-cardiac arrest interventions during emergency care.
The platform uses a master protocol structure with shared eligibility criteria, infrastructure, data management systems, and follow-up procedures across multiple intervention domains. Adult patients with persistent coma after ROSC who require intensive care are screened for eligibility under the master protocol. Individual domains may apply additional domain-specific inclusion and exclusion criteria.
The current platform includes multiple intervention domains evaluating different post-cardiac arrest care strategies.
One domain evaluates early head positioning strategies during intensive care management. This domain compares head elevation positioning (30°-45°) with near-supine positioning (0°-10°) initiated early after ICU admission in order to determine whether head positioning influences neurological recovery, mortality, and complications associated with cerebral perfusion, intracranial pressure, or respiratory management.
Another domain evaluates early targeted temperature management strategies in patients with non-shockable cardiac arrest rhythms. This domain compares early hypothermia (33-34°C) with normothermia (36-37.5°C) initiated as early as possible after ROSC in order to evaluate whether early temperature control improves neurological outcomes and survival.
Participants may simultaneously participate in more than one intervention domain when eligibility criteria are met. Aside from the assigned study interventions, all other intensive care management is performed according to local institutional practice and study protocols.
The primary and secondary outcomes differ according to each intervention domain and include neurological outcomes assessed using the modified Rankin Scale (mRS), mortality, and predefined safety outcomes. Follow-up assessments are performed during hospitalization and at 30 and 90 days after hospital admission.
Because eligible patients are critically ill and frequently incapable of providing prospective informed consent at the time of enrollment, this study permits deferred consent procedures in accordance with Japanese ethical guidelines for emergency research. Consent from legally acceptable representatives or patients themselves is obtained as soon as feasible after hospital admission whenever possible.
The study also includes predefined interim analyses and centralized data management using REDCap-based electronic data capture systems. Statistical analyses are performed using intention-to-treat principles with methods appropriate for cluster-randomized crossover trial designs.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This study is a multicenter cluster-randomized crossover platform trial evaluating post-cardiac arrest care strategies in adult patients with post-cardiac arrest syndrome. Participating hospitals are assigned to predefined intervention strategies at the institutional level and cross over between strategies at predefined intervals. The platform includes multiple intervention domains, including head positioning and temperature control strategies. Individual participants may be enrolled in one or more active intervention domains according to platform availability and eligibility. Enrollment reflects Domain 1 (head positioning, n=630); some patients are co-enrolled in Domain 2 (temperature control, n=240) based on rhythm eligibility
| Arm | Type | Receives |
|---|---|---|
| Head Positioning Strategy (near-supine vs head elevation) | Experimental | Procedure: Head PositioningParticipants receive institutionally assigned post-cardiac arrest head positioning strategies according to the cluster-randomized crossover platform protocol, including head elevation (30°-45°) or near-supine positioning (0°-10°). |
| Temperature Control Strategy (hypothermia vs normothermia) | Experimental | Other: Temperature ControlParticipants receive institutionally assigned post-cardiac arrest temperature control strategies according to the cluster-randomized crossover platform protocol, including targeted hypothermia (33-34°C) or normothermia/fever prevention strategies (36-37.5°C). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Adult patients aged 18 years or older
- Return of spontaneous circulation after cardiac arrest
- Persistent coma after return of spontaneous circulation (GCS motor score <6)
- Requirement for intensive care management
- Non-traumatic out-of-hospital or in-hospital cardiac arrest
Key exclusion criteria (25 listed)
- Refusal of intensive care management
- Extracorporeal cardiopulmonary resuscitation (ECPR)
- Pregnancy or possible pregnancy
- Cardiac arrest due to intracranial hemorrhage, subarachnoid hemorrhage, cerebral infarction, acute aortic dissection, or terminal cancer (including suspected cases)
- Severe chronic obstructive pulmonary disease requiring home oxygen therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Head PositioningInstitution-level assignment to predefined head positioning strategies during post-cardiac arrest intensive care management, including head elevation (30°-45°) or near-supine positioning (0°-10°). | Procedure or surgery | Head Positioning Strategy (near-supine vs head elevation) |
| Temperature ControlInstitution-level assignment to predefined temperature control strategies during post-cardiac arrest intensive care management, including targeted hypothermia (33-34°C) or normothermia/fever prevention strategies (36-37.5°C). | Other | Temperature Control Strategy (hypothermia vs normothermia) |
Primary outcome
Favorable neurological outcome (modified Rankin Scale ≤3) on Day 90 in the head positioning domain
Time frame: 90 days after hospital admission
Comparison of Favorable neurological outcome (modified Rankin Scale ≤3) on Day 90 between institutionally assigned head positioning strategies in adult patients with post-cardiac arrest syndrome.
Favorable neurological outcome (modified Rankin Scale ≤3) on Day 90 in the temperature control domain
Time frame: 90 days after hospital admission
Comparison of neurological outcomes between institutionally assigned temperature control strategies in adult patients with post-cardiac arrest syndrome and non-shockable initial rhythms.
4 secondary outcomes
mRS ≤3 on Day 30
Time frame: 30 days after hospital admission
mRS ≤3 on Day 30
Time frame: 30 days after hospital admission
All-cause mortality on Day 30 and Day 90
Time frame: 30 days and 90 days after hospital admission
All-cause mortality on Day 30 and Day 90
Time frame: 30 days and 90 days after hospital admission
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Cardiac Arrest (CA)
Recruiting
The VENTOR Clinical Study
Cardiac Arrest (CA)
RecruitingObservational study
Physiology-directed Epinephrine Dosing in Pediatric Cardiac Arrest
Cardiac Arrest (CA)
Recruiting
Optimal Ventilation for Cardiac Arrest
Cardiac Arrest (CA)
Not yet recruiting
The OXY-VENT Study
Cardiac Arrest (CA), Cardiopulmonary Resuscitation (CPR)
Not yet recruitingObservational study
Integrated Near-Infrared Spectroscopy and Hemodynamic Monitoring for Cerebral Autoregulation in Post-Cardiac Arrest Care Neuroprognostication
Cardiac Arrest (CA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
12 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Head Positioning in people with Cardiac Arrest (CA) and Post Cardiac Arrest Syndrome, run by Kagawa University at 12 sites in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 12 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yasuhiro Kuroda, M.D, Ph.D (+81-87-891-2392, bpt-pcas@googlegroups.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Favorable neurological outcome (modified Rankin Scale ≤3) on Day 90 in the head positioning domain (time frame: 90 days after hospital admission). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2026.